Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...

With vasa-Cas9, high efficiency and self-limiting suppression was achieved. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging due to its high off-target activity.

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

Bayer is just the latest in a string of big pharma companies to invest in firms with CRISPR-Cas9 expertise, of which CRISPR Therapeutics is one of four leading players.

Both Cas9 and Cas12a cleave DNA, but they differ in how they cut the molecule.

Trusted by leading innovators worldwide, ERS Genomics is committed to providing responsible and effective access to CRISPR/Cas9 technology. To support small and early-stage organizations ...